Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/264"

Predicate	Value (sorted: none)
rdf:type	?:Evidence
rdf:type	?:Item
rdfs:label	"evidence_1896"
?:Evidence_type	?:Non_traceable_Drug_Label_Statement
?:Evidence_assump_list_id	"50"
?:Evidence_enzyme_system	""
?:claim_assumed_valid_for_evidence_application_evidence_1896	?:S-warfarin_primary_total_clearance_enzyme_cyp2c9
dc:creator	"boycer"
dc:date	"09/24/2009 15:41:53"
?:content	"Drug-Drug Interactions: ... Coadministration of multiple doses of zafirlukast (160 mg/day) to steady-state with a single 25 mg dose of warfarin (a substrate of CYP2C9) resulted in a significant increase in the mean AUC (+63%) and half-life (+36%) of S-warfarin. The mean prothrombin time increased by approximately 35%. The pharmacokinetics of zafirlukast were unaffected by coadministration with warfarin."
rdfs:seeAlso	?:5550433b-8c9c-4378-058f-6bb724c4f18c

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl

The resource appears as object in one triple:

{ zafirlukast_inhibits_cyp2c9, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1896 }

Context graph